Literature DB >> 2917594

Pharmacokinetics of cefonicid in children.

M Furlanut1, R D'Elia, E Riva, F Pasinelli.   

Abstract

The pharmacokinetics of cefonicid was studied in 17 children requiring antibiotic treatment for respiratory or urinary tract infections. After informed consent had been obtained from the parents, a single dose of cefonicid 50 mg/kg/body weight was given by intramuscular injection. The mean peak serum concentration of 212.63 micrograms/ml was reached at 1.00 h, as absorption occurred at a very fast rate with a mean constant of 3.24 h-1. Mean values for half-life, apparent volume of distribution (Vz), total body clearance (CL), and renal clearance (CLR) were 3.24 h, 0.21 l.kg-1, 16.67 ml.min-1 and 13.60 ml.min-1 respectively. There was an inverse relationship between age and Vz, whereas CL and CLR were positively correlated with age. Cefonicid concentrations in urine were many times higher than the MICs of susceptible strains of bacteria. The study demonstrated that i.m. cefonicid 50 mg.kg-1 gave serum concentrations well within the therapeutic range for susceptible bacteria, and that its pharmacokinetic properties allow single daily doses to be used to treat infections in children.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917594     DOI: 10.1007/BF00561029

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Clinical and economic impact of cefonicid. A symposium, San Francisco, California, November 18-19, 1982.

Authors: 
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

3.  High-performance liquid chromatographic determination of cefonicid in human plasma and urine.

Authors:  E Brendel; M Zschunke; I Meineke
Journal:  J Chromatogr       Date:  1985-05-03

Review 4.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

5.  Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infections.

Authors:  E G Chadwick; R Yogev; S T Shulman; R E Weinfeld; I H Patel
Journal:  J Pediatr       Date:  1983-01       Impact factor: 4.406

Review 6.  Review of cefonicid, a long-acting cephalosporin.

Authors:  M N Dudley; R Quintiliani; C H Nightingale
Journal:  Clin Pharm       Date:  1984 Jan-Feb

7.  Cefonicid kinetics in subjects with normal and impaired renal function.

Authors:  A D Blair; B M Maxwell; S C Forland; L Jacob; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

8.  Kinetics and renal handling of cefonicid.

Authors:  D Pitkin; J Dubb; P Actor; F Alexander; S Ehrlich; R Familiar; R Stote
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  An overview: evaluation of cefonicid in infections of the urinary tract, lower respiratory tract, and skin and soft tissue.

Authors:  D Kaye
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

Review 10.  Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects.

Authors:  R E Pontzer; D Kaye
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.